Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery.
The poor patency rates for coronary artery bypass grafting (CABG) using autologous saphenous vein necessitate the need for continued research into the potential clinical utility of gene therapy. Bypass grafting is ideally suited for gene therapy, as graft can be genetically modified ex vivo prior to grafting in the coronary vasculature. Research to date has demonstrated effective blockade of late vein graft failure through overexpression of a variety of transgenes that modulate the proliferative, migratory and/or apoptotic indexes of cells in the graft wall. This has resulted in a substantial wealth of preclinical data that support advancement to clinical trials. Future translation into clinical trials will ensure that this exciting and highly relevant area of gene therapy is fully evaluated for potential routine clinical practice to improve patency rates of bypass graft procedures involving saphenous vein.
Baker
Andrew H
AH
Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. ab11f@clinmed.gla.ac.uk
Yim
Anthony P C
AP
Wan
Song
S
D000256:Adenoviridae; D001026:Coronary Artery Bypass / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D011475:Prosthesis Failure; D012501:Saphenous Vein / Q000637:transplantation; D014654:Vascular Patency